Skip to main content
2024 ISPE Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

J. Bradley Layton, PhD, FISPE (he/him/his)

Director, Epidemiology
RTI Health Solutions
Research Triangle Park, United States

Bradley Layton, PhD, is a Director of Epidemiology at RTI Health Solutions. He has considerable experience in the design, conduct, analysis, and reporting of epidemiologic studies and has over 11 years of experience in the field of pharmacoepidemiology. His work includes performing regulatory-required safety studies and RWE safety and effectiveness studies for regualtory decision-making. His experience and publications span a wide range of substantive areas, including renal, cardiovascular, men's health, vaccines, and pregnancy, and incorporate multidatabase and multinational studies. Dr. Layton also has experience with epidemiologic methods, lecturing to clinical and public health audiences about observational study design, large database utilization, and propensity score analysis. Dr. Layton received his master's and doctorate degrees in epidemiology from the Department of Epidemiology in the Gillings School of Global Public Health, University of North Carolina at Chapel Hill, focusing in pharmacoepidemiology with an emphasis in renal disease. Prior to joining RTI-HS, he was a member of the faculty in the Pharmacoepidemiology Program in the University of North Carolina Department of Epidemiology, where he accrued vast experience leading studies that utilized secondary health care data sets to evaluate pharmaceutical use, safety, and effectiveness, and he is currently an adjunct assistant professor at the University of North Carolina. As a faculty member, he organized and taught in several workshops and training courses for epidemiologists in pharmaceutical companies, as well as a set of methods workshops for epidemiologists at the Food and Drug Administration. Dr. Layton also is an active member of the International Society of Pharmacoepidemiology, having served as a previous chair of the Vaccine SIG and on the Scientific Program Committee since 2014.

Disclosure information not submitted.

Presentation(s):

Email J. Bradley